STOCK TITAN

Minerva Neurosciences (NERV) director awarded 50,000 stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Minerva Neurosciences, Inc. director G Jan Van Heek received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $4.68 per share and expire on June 2, 2036.

The 50,000 options vest in four equal quarterly installments, with one-quarter vesting three months after June 3, 2026 and additional quarters vesting every three months after that. Vesting requires continued service as a non-employee director on each vesting date.

Positive

  • None.

Negative

  • None.
Insider VAN HEEK G JAN
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 50,000 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 50,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 50,000 options Stock Option (right to buy) granted to director
Exercise price $4.68 per share Conversion or exercise price of stock options
Expiration date June 2, 2036 Option term end date
Post-grant derivative holdings 50,000 options Total derivative securities following transaction
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
exercise price financial
"conversion_or_exercise_price: "4.6800""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-06-02T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
non-employee director financial
"continued service of the Reporting Person as a non-employee director"
vesting financial
"The shares subject to this option vest in four equal quarterly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
VAN HEEK G JAN

(Last)(First)(Middle)
C/O MINERVA NEUROSCIENCES, INC.
1500 DISTRICT AVENUE

(Street)
BURLINGTON MASSACHUSETTS 01803

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Minerva Neurosciences, Inc. [ NERV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$4.6806/03/2026A50,000 (1)06/02/2036Common Stock50,000$050,000D
Explanation of Responses:
1. The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 3, 2026 and an additional 1/4 vesting every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date.
/s/ Frederick Ahlholm, Attorney-in-Fact06/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Minerva Neurosciences (NERV) disclose in this Form 4?

Minerva Neurosciences reported that director G Jan Van Heek received a grant of stock options for 50,000 shares of common stock. These options were awarded as compensation and are not an open-market purchase or sale of existing shares.

How many Minerva Neurosciences (NERV) options were granted to the director?

The director was granted stock options covering 50,000 shares of Minerva Neurosciences common stock. This entire amount is reflected as derivative securities following the transaction and represents a new compensation award rather than a market trade.

What is the exercise price and expiration date of the NERV stock options?

The granted stock options have an exercise price of $4.68 per share and expire on June 2, 2036. The option holder may exercise vested portions at this fixed price any time before the expiration, subject to plan and service conditions.

How do the Minerva Neurosciences (NERV) director’s options vest?

The 50,000 options vest in four equal quarterly installments. One-quarter vests three months after June 3, 2026, with additional quarters vesting every three months thereafter. Each vesting event requires continued service as a non-employee director on that date.

Did the Minerva Neurosciences (NERV) director buy or sell common shares in this filing?

No common shares were bought or sold in the market in this filing. The director received a grant of stock options as compensation, classified as an acquisition of derivative securities rather than an open-market purchase or sale.

How many derivative securities does the Minerva Neurosciences (NERV) director hold after this grant?

After this grant, the Form 4 shows the director holding 50,000 derivative securities in the form of stock options. This total corresponds to the newly granted options that can convert into common shares upon exercise, subject to vesting conditions.